Skip to content Skip to sidebar Skip to footer

Insulin Pumps Have a Moment: Why Insulet Is Growing Like a Tech Stock, Not a Medical Device -( $PODD $TNDM $MODD )

Insulin pumps are having a moment, and this time it is not just Wall Street that is impressed—it is patients, payers, and, increasingly, competitors playing catch‑up.

Insulet’s Growth Streak Enters Double Digits

Insulet (PODD) closed 2025 like a company that never got the memo about “mature medtech,” delivering approximately 31% revenue growth in the fourth quarter to about 784 million dollars and crossing roughly 2.7 billion dollars for the full year. That marked its 10th consecutive year of more than 20% constant‑currency revenue expansion, an achievement more typical of hot software names than a maker of wearable insulin pumps.

The company’s Omnipod franchise did most of the heavy lifting, with Pod revenue growing in the low‑30% range and essentially accounting for the entire topline. Management highlighted another year of record new customer starts as patients continued migrating from multiple daily injections to automated delivery, a structural shift that still has considerable runway.

Margin Muscle in a Competitive Market

Insulet did not just grow; it grew with discipline. Gross margin in the fourth quarter expanded to roughly 72.5%, up about 40 basis points year over year, while full‑year gross margin finished around 71.6%, nearly 180 basis points higher than 2024. Operating income climbed to about 146 million dollars in Q4, or roughly 18.7% of revenue, with adjusted operating income moving in lockstep and advancing 30 to 40 basis points.investor.insulet+3

For 2025 as a whole, Insulet generated operating income in the mid‑400‑million‑dollar range and lifted operating margin by more than two percentage points, even as it invested in expanding capacity, innovation, and commercial reach. Free cash flow topped roughly 375 million dollars, offering investors the comforting reminder that rapid growth and cash generation are not mutually exclusive concepts.

Diabetes Care: From Niche to Strategic Asset

Insulet’s sustained growth says as much about the diabetes technology market as it does about the company. Management pointed to continued adoption of automated insulin delivery systems as physicians grow more comfortable prescribing pumps for a broader swath of patients, including those earlier in the disease course. With U.S. revenue growing in the high‑20% range and international sales advancing at an even faster clip in the fourth quarter, Omnipod is increasingly a global story rather than a North American niche. The U.S. market size is now at +27 million people with diabetes, where 4.88 million require daily insulin (2M Type 1, 2.88M Type 2). Only 20% of insulin dependent people with diabetes use a pump for insulin delivery. 80% rely on multiple daily injections (MDI).

Analysts now expect Insulet’s revenue to grow around the high‑teens to roughly 20% over the next year, slower than the recent breakneck pace but still robust for a company already above 2.5 billion dollars in sales. That leaves Insulet in the enviable position of arguing not whether it can grow, but whether it chooses to prioritize margin expansion, share gains, or both—an executive‑level version of having to pick just one dessert.

Modular Medical: The Challenger at the Gate

If Insulet represents the established growth franchise, Modular Medical (NASDAQ: MODD) is the challenger trying to re‑write the script on affordability and access. The company recently announced a 12 million dollar public offering priced at a premium to market, a notable show of confidence for a small‑cap medtech name in a still‑selective funding environment. The deal, led by Maxim Group, includes immediately exercisable warrants with a five‑year term, giving investors both capital appreciation potential and time to see the commercial story unfold.

Modular Medical’s pitch is elegantly simple: take lessons learned from prior pump platforms and engineer a system aimed at lower cost and easier use, broadening the market beyond today’s more complex devices. The company’s founder, Paul DiPerna, previously founded Tandem Diabetes (TNDM) and designed its t:slim pump, giving this new venture a pedigree that has not gone unnoticed among diabetes‑tech watchers. For a market where many patients still rely on injections for cost or usability reasons, a lower‑friction pump could be more than a niche—it could be an on‑ramp. The U.S. market size is now at +27 million people with diabetes, where 4.88 million require daily insulin (2M Type 1, 2.88M Type 2). Only 20% of insulin dependent people with diabetes use a pump for insulin delivery. 80% rely on multiple daily injections (MDI). HCPs fairly consistently indicated that about 25% of their MDI population are “almost pumpers”, meaning
that they have considered going on a pump, understand pump therapy benefits, but want something
simpler that doesn’t have all the “bells and whistles’, which is estimated to be ~$3 billion US market opportunity.

Two Paths, One Market: Insulet vs. Modular Medical

Investors now find themselves watching two very different approaches to the same problem: how to deliver insulin more effectively, with fewer trade‑offs for patients and payers.

CompanyCore focus2025/Recent scaleStrategic lever
Insulet (PODD)Tubeless Omnipod AID systems~2.7B dollars revenue, 31% growth Premium, high‑growth global platform
Modular MedicalLower‑cost, simplified pump platformDevelopment‑stage, raised 12M dollars this weekAffordability, ease of use

Insulet enjoys the advantages of scale, brand recognition, and a decade‑long track record of 20%‑plus growth, but it must continue innovating as competition intensifies and payers scrutinize every incremental dollar. Modular Medical (MODD), by contrast, is betting that a leaner design via their insulin pump called Pivot and a focus on lower cost could open new segments of the market—provided it can execute on manufacturing, regulatory milestones, and commercial rollout.

For Wall Street, the setup is familiar: a market leader proving the category’s durability and a newcomer seeking to expand the pie rather than simply slicing it thinner. For patients, it is a rare case where investors’ enthusiasm and clinical needs are aligned; more options in insulin delivery typically translate to better matches for individual lifestyles and budgets.

Outlook: An Expanding Field, Not a Zero‑Sum Game

Looking ahead, Insulet has guided to continued double‑digit growth, underpinned by ongoing conversion from injections, expansion into international markets, and further penetration of automated insulin delivery in both Type 1 and select Type 2 populations. The company’s strengthening balance sheet and rising free cash flow give it ample flexibility to invest in R&D, capacity, and potential partnerships, all while nudging margins higher over time.

Modular Medical (MODD), for its part, now has fresh capital and a longer runway to pursue its mission of making pump therapy more attainable. If the company can translate engineering expertise into a commercially viable, lower‑cost product, it may help expand the overall pump‑eligible population rather than simply vie for share within it—a scenario where the leader and the upstart both stand to benefit.

In a market long defined by trade‑offs—control versus convenience, innovation versus cost—the emerging narrative in diabetes tech is refreshingly constructive. Insulet is proving that scale and innovation can coexist, while Modular Medical (MODD) is trying to ensure that innovation does not become a luxury good, and that might be the kind of competition patients would not mind seeing a lot more of.

The Sources

Here is a clean, numbered source list with live links:

  1. Insulet Reports Fourth Quarter and Full Year 2025 Results (Insulet IR)
    https://investor.insulet.com/news/news-details/2026/Insulet-Reports-Fourth-Quarter-and-Full-Year-2025-Results/default.aspx[investor.insulet]​
  2. Insulet Reports Fourth Quarter and Full Year 2025 Results (Yahoo Finance syndication)
    https://finance.yahoo.com/news/insulet-reports-fourth-quarter-full-120000955.html[finance.yahoo]​
  3. Insulet Corporation Q4 2025 Earnings Call Summary
    https://finance.yahoo.com/news/insulet-corporation-q4-2025-earnings-133000560.html[finance.yahoo]​
  4. Insulet Corp (PODD) Q4 2025 Earnings Call Highlights
    https://finance.yahoo.com/news/insulet-corp-podd-q4-2025-190048367.html[finance.yahoo]​
  5. Insulet (NASDAQ:PODD) Surprises With Q4 CY2025 Sales
    https://finance.yahoo.com/news/insulet-nasdaq-podd-surprises-q4-120738996.html[finance.yahoo]​
  6. Insulet Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025
    https://www.marketscreener.com/news/insulet-corporation-reports-earnings-results-for-the-fourth-quarter-and-full-year-ended-dece-xxxx[marketscreener]​
  7. Insulet Q4 2025 Slides: Revenue Soars 31%, Stock Jumps on Strong 2026 Outlook
    https://www.investing.com/news/company-news/insulet-q4-2025-slides-revenue-soars-31-stock-jumps-on-strong-2026-outlook-93CH-4511[investing]​
  8. Insulet Stock Rises Before Hours on Q4 Beats, 31% Sales Growth
    https://www.drugdeliverybusiness.com/insulet-q4-2025-beats-stock-growth/[drugdeliverybusiness]​
  9. Insulet Boosts Buyback, Posts 31% 2025 Revenue Growth
    https://www.stocktitan.net/sec-filings/PODD/8-k-insulet-corp-reports-material-event-8b015c630092.html[stocktitan]​
  10. Modular Medical Announces 12.0 Million Public Offering Priced at a Premium to Market
    https://finance.yahoo.com/news/modular-medical-announces-12-0-142700002.html[finance.yahoo]​
  11. Modular Medical Announces 12.0 Million Public Offering Priced at a Premium to Market (press release host)
    https://www.biospace.com/press-releases/modular-medical-announces-12-0-million-public-offering-priced-at-a-premium-to-market[biospace]​
  12. Modular Medical Prices 12M Stock and Warrant Sale
    https://www.stocktitan.net/news/MODD/modular-medical-announces-12-0-million-public-offering-priced-at-a-94hlmxlvuulh.html[stocktitan]​
  13. Modular Medical Begins Production of Insulin Pump Components
    https://www.streetinsider.com/Corporate+News/Modular+Medical+begins+production+of+insulin+pump+components/25943724.html[streetinsider]​
  14. Modular Medical Achieves Key Manufacturing Milestone for Pivot Tubeless Insulin Patch Pump
    https://nationaltoday.com/us/ca/san-diego/news/2026/02/05/modular-medical-achieves-key-manufacturing-milestone-for-pivot-tubeless-insulin-patch-pump[nationaltoday]​

March 4, 2026 – Markets Hold Their Nerve: Iran Blinks, Bitcoin Winks, and Bulls Tiptoe Back In -( $ASNS $BTC $DV $EPRX $FIGS $GOVX $INTG $MODD $MRNA $NOK $NVDA Rise!)

US stocks rebounded on Wednesday, March 4, 2026, as easing fears around the Iran conflict and steadier oil prices helped buyers step back in, while Bitcoin extended its latest surge.

Index performance

The major US benchmarks climbed, recapturing a chunk of the prior session’s losses tied to Middle East tensions.finance.yahoo+2

  • The S&P 500 rose about 0.78%, closing near 6,869.50 after trading around 6,877 intraday.
  • The Dow Jones Industrial Average added roughly 0.49%, finishing around 48,739.41.
  • The Nasdaq Composite outperformed with a gain of about 1.29%, ending at 22,807.48 as growth and tech bounced.
  • The Russell 2000 advanced roughly 1.06%, signaling renewed appetite for smaller caps after recent underperformance.

This rebound came after a choppy stretch in which war headlines had driven sharp intraday swings and a notable pullback in the Dow.

Macro and geopolitics

Traders remained focused on developments in the Iran conflict, but the tone shifted as hopes for at least a pause in escalation nudged volatility lower. Oil, which had spiked on supply-risk fears, stabilized on Wednesday; Crude finished the day roughly flat around $76.16/bbl per barrel, removing an immediate pressure point for equities.

Better‑than‑feared US economic readings and still‑solid corporate commentary helped offset geopolitical anxiety, reinforcing the narrative that growth remains intact even as markets digest higher energy volatility. US private employers added 63k in February, which exceeded expectations according to the private payroll processor ADP.

Sectors and themes

Risk appetite rotated back toward growth, with technology and communication-services names leading the Nasdaq’s rebound. Defense and energy, which had already benefited from prior days’ tension‑driven flows, held firm as crude prices leveled out, while more defensive areas like utilities and staples lagged the broader move higher. Smaller caps’ outperformance hinted at a modest revival of domestic cyclical plays, though index-level data show the S&P 500 is still fractionally lower week‑to‑date, underscoring how fragile sentiment remains.

Crypto and Bitcoin

In digital assets, Bitcoin (BTC) pushed higher, trading back above the high‑$60,000s to low‑$70,000s range as traders leaned into the idea that institutional demand and ETF inflows could sustain the rally. The move comes against a backdrop of mixed signals: on-chain and price‑trend gauges remain cautious after a sharp pullback over the past month, even as some strategists highlight upside scenarios into the $100,000‑plus area if current inflows persist. Crypto’s strength added to the day’s broader “risk‑on” tone, with Bitcoin’s rebound standing in contrast to the defensive posture that dominated when Middle East headlines first hit earlier in the week.

Big picture for investors

Despite Wednesday’s relief rally, the S&P 500 and Dow are only roughly flat to slightly lower for the week, a reminder that geopolitical risk and headline‑driven swings remain central to the tape. For now, the market appears to be in a headline‑sensitive holding pattern: dips tied to Iran and oil shocks are drawing buyers, but sustained upside will likely hinge on clearer evidence that the conflict is contained and that earnings can absorb higher energy and funding costs.

VP Watchlist Updates

Below is an update‑style snapshot on the VP Watchlist names for the week, focused on recent catalysts, positioning, and narrative rather than precise price moves.

Eupraxia Pharmaceuticals (EPRX, $8.18, +2%)

Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, recently announced the successful closing of its previously announced public offering (the “Offering”) of 7,607,145 common shares of the Company (the “Common Shares”), which includes the full exercise of the option to purchase additional shares granted to the underwriters, at a price to the public of US$7.00 per Common Share, and pre-funded warrants to purchase up to 1,428,571 Common Shares in lieu thereof (the “Pre-Funded Warrants”) at a price of US$6.99999 per Pre-Funded Warrant, which equals the public offering price per Common Share less the C$0.000001 per share exercise price of each Pre-Funded Warrant, for gross proceeds of approximately US$63.2 million, before deducting the underwriting commissions and estimated expenses incurred in connection with the Offering.“We are pleased to complete this financing, allowing us to significantly expand our pipeline, reach several additional development milestones with EP-104GI for eosinophilic esophagitis, and make meaningful progress towards commercial readiness,” said James Helliwell, CEO of Eupraxia. “We appreciate the support from both existing and new investors as we execute our mission and pursue the next phase of growth for Eupraxia.” Cantor and LifeSci Capital acted as joint book-running managers for the Offering. Bloom Burton and Craig-Hallum also acted as co-managers for the Offering. As previously stated, the Company intends to use the net proceeds from the Offering primarily for the continued advancement of EP-104GI for Eosinophilic Esophagitis, including the completion of ongoing preclinical studies, and Phase 2 clinical trials, preparations for a Phase 3 clinical trial including the related regulatory submissions, and manufacturing activities, and to undertake the necessary commercial/market development activities to prepare for the eventual product launch. The Company also intends to use a portion of the proceeds to accelerate and expand its plans to pursue clinical studies with EP-104GI in multiple additional gastrointestinal indications, including in esophageal strictures and fibrostenotic Crohn’s disease. A portion of the proceeds will be allocated to research and development of additional pipeline candidates, business development initiatives, and general corporate purposes, which may include but are not limited to employee salaries, working capital, leases for facilities, administrative expenses, and capital expenditures. The Company may also use a portion of the proceeds to expand its intellectual property portfolio and strengthen its corporate infrastructure to support future growth.

Modular Medical (MODD $.1899, +13.04%)

FIGS, Inc. (FIGS, $16.967, +.12%)

  • FIGS, the direct‑to‑consumer healthcare apparel brand, operates at the intersection of e‑commerce and specialty retail, with a loyal professional customer base and a growing product portfolio. While macro headwinds and digital‑ad volatility have pressured some consumer names, FIGS’ brand equity in the medical community and ongoing product innovation offer levers for renewed growth as conditions normalize.
  • After the close (Feb. 26), FIGS released its fourth quarter and full year 2025 financial results and published a financial highlights presentation on its investor relations highlighting the following: Exceeded Top and Bottom Line Expectations, Grew Q4 2025 Net Revenues 33.0% to a Record $201.9 Million, Achieved Q4 2025 Net Income Margin of 9.2% and Adjusted EBITDA Margin of 13.2% & Plans Low Double-Digit Net Revenues Growth and Margin Expansion in FY 2026. FIGS shares have traded up to $13.74 in the aftermarket today.

GeoVax Labs (GOVX, $1.71, +8,92%)

DoubleVerify (DV, $10.34, +1.77%)

  • DoubleVerify, the leading software platform for digital media measurement, data and analytics, today announced financial results for the fourth quarter and full year ended December 31, 2025 and highlighted the following: Increased 2025 Revenue by 14% Year-over-Year to $748.3 Million, Driven by Global Growth in Social, CTV Measurement, and Programmatic Activation, Achieved 2025 Net Income of $50.7 Million and Adjusted EBITDA of $245.6 Million, representing a 33% Adjusted EBITDA margin, & $300 Million Authorized for Share Repurchases, the Largest Amount in DoubleVerify’s History.

The InterGroup Corporation (INTG, $32.27, +3.03%)

  • InterGroup Corporation delivered (Feb. 17) a notably stronger quarter, highlighted by a 20% jump in total revenue to $17.3 million and a 27% surge in hotel revenue as renovated rooms returned to service and travel demand improved. The company swung from a prior-year net loss to $1.0 million in net income, with operating income more than doubling to $2.0 million, underscoring better cost control and improved operating efficiency. Management further enhanced liquidity and sharpened strategic focus by selling a non-core 12‑unit Los Angeles multifamily property, generating a meaningful gain and additional working capital while maintaining stable performance across its real estate portfolio.

Serina Therapeutics (SER, $1.67)

  • Serina Therapeutics, a clinical-stage biotechnology company advancing drug candidates enabled by its proprietary POZ Platform™ drug optimization technology, announced (Feb. 19) that the first patient has been enrolled in the Company’s Phase 1b registrational trial evaluating. The Phase 1b registrational study is designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of SER-252 in patients with advanced Parkinson’s disease whose symptoms are inadequately controlled by current standard-of-care therapies. Serina remains on track to initiate dosing during the current quarter, consistent with previously disclosed guidance.

Volato Group, Inc. (SOAR, $3446, +1.77%) & M2i Global, Inc. (MTWO)

  • Volato and M2i Global reaffirmed their goal of closing their business combination in the first quarter of 2026, citing steady advancement through SEC review and integration planning as they move toward a combined listing. The deal, originally announced in 2025, will effectively transition Volato from a pure‑play private aviation operator into a diversified platform spanning aviation technology and critical minerals, with M2i shareholders expected to own the majority of the combined entity. Operationally, the partnership is already visible: the two companies recently initiated their first shipment of titanium ore from Western Australia to the United States from Titanium X, underscoring how the critical‑minerals vertical could become a meaningful growth engine as domestic supply‑chain security rises in strategic importance.
  • On Feb. 4, M2i Global,Inc.along with Volato Group, Inc. announced that Titanium X has initiated its first shipment of titanium ore from Western Australia to the U.S. under its collaboration agreement.

NVIDIA (NVDA, $183.04, +1.66%)

  • Nvidia delivered strong fourth-quarter results recently, posting revenue of $68.1 billion, well above analyst expectations. Looking ahead, the company projects $7.8 billion in revenue for the first quarter of 2026, reflecting continued robust demand for its AI chips even amid broader market headwinds.

McDonald’s (MCD, $331.74)

  • Options data around the February 2026 expiries highlight active positioning near the 300–305 strike range, consistent with expectations for steady but not explosive upside from here.
  • In the run-up to World Protein Day on 27th February, McDonald’s India (West & South), owned and operated by Westlife Foodworld, is celebrating Protein Week, reinforcing its leadership in nutrition-led innovation. Making protein more accessible, affordable and customizable, Indian consumers can use the McDonald’s app to explore these nutritious offerings and avail of protein burgers starting at just INR 69. Enhancing this convenience, consumers ordering via McDelivery can also enjoy free delivery on the Protein Plus meal range.

Nokia (NOK, $8.15, +.99%)

Opendoor (OPEN, $4.88)

Actelis Networks, Inc. (NASDAQ: ASNS, $.5393, +186.56%)

Actelis Networks, Inc. (NASDAQ: ASNS), a market leader in cyber-hardened, rapid-deployment networking solutions for IoT and broadband applications, today announced that it has received an order to supply its hybrid fiber-copper networking solution in support of a major California Department of Transportation (Caltrans) infrastructure modernization project in San Mateo County. The order continues a pattern of growing adoption of Actelis’ solutions by government transportation agencies across the United States.

Moderna (MRNA, $57.80, +15.99%)

Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust lipid nanoparticle (LNP) patent portfolio and a subsidiary of Roivant Sciences Ltd. (Nasdaq: ROIV), and Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company focused on infectious disease, today announced that they have entered into a $2.25 billion global settlement with Moderna, Inc. to resolve all U.S. and international enforcement actions involving Moderna’s unauthorized use of Genevant’s and Arbutus’ LNP delivery technology in its COVID-19 vaccines, including Spikevax®.

The Sources

  1. Yahoo Finance – “Stock market today: Dow, S&P 500, Nasdaq rebound on hopes of Iran deescalation as Bitcoin surges”
    https://finance.yahoo.com/news/live/stock-market-today-dow-sp-500-nasdaq-rebound-on-hopes-of-iran-deescalation-as-bitcoin-surges-210937794.html
  2. Yahoo Finance – “Wednesday, March 4, 2026”
    https://finance.yahoo.com/news/wednesday-march-4-2026-050300506.html
  3. Yahoo Finance – “How major US stock indexes fared Wednesday, 3/4/2026”
    https://finance.yahoo.com/news/major-us-stock-indexes-fared-212254691.html
  4. Yahoo Finance – “Stock Market News for Mar 3, 2026”
    https://finance.yahoo.com/news/stock-market-news-mar-3-142000562.html
  5. Wall Street Journal – “Stock Market Today: Dow Rises, Oil Prices Stabilize” (Live coverage, March 4, 2026)
    https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-03-04-2026
  6. Trading Economics – “United States Stock Market Index”
    https://tradingeconomics.com/united-states/stock-market
  7. Yahoo Finance – “Bitcoin High-Stakes March: $120K Forecasts Meet the $60K–$70K …”
    https://finance.yahoo.com/news/bitcoin-high-stakes-march-120k-103819836.html
  8. CoinCodex – “Bitcoin is Predicted to Reach $73,640 By Mar 03, 2026”
    https://coincodex.com/article/82290/bitcoin-prediction-february-26-2026/
  9. Robinhood – “Bitcoin price on Mar 4, 2026 at 10pm EST – Crypto Prediction Market”
    https://robinhood.com/us/en/prediction-markets/crypto/events/bitcoin-price-on-mar-4-2026-at-10pm-est-mar-03-2026/

From Coal to Code: TerraPower, Oklo and Microsoft Plug the AI Era into Next-Gen Nuclear -( $MSFT $OKLO )

America’s nuclear sector just received something rarer than bipartisan kumbaya on Capitol Hill: a first-of-its-kind commercial construction permit for an advanced reactor, signaling that the atomic age is getting a sequel with better graphics, tighter scripting—and, this time, a climate mandate. For Wall Street and Silicon Valley alike, the message is straightforward: the Nuclear Regulatory Commission is no longer a museum; it is open for new business in electrons.

Gates’ TerraPower Steps Onto Center Stage

At the center of this shift is the Natrium project in Kemmerer, Wyoming, developed by TerraPower, the nuclear innovation company founded by Bill Gates. The Natrium design is a 345 megawatt sodium-cooled fast reactor paired with a molten-salt energy storage system that can flex output to 500 megawatts—enough to power roughly 400,000 homes during peak periods. That built-in storage allows the plant to ramp like a battery while still behaving like dependable baseload, giving grid operators the kind of dispatchable, carbon-free power they usually only dream about in PowerPoint.

The Wyoming site, being built near a retiring coal plant, is the country’s flagship “coal-to-nuclear” conversion and the first utility-scale advanced nuclear project to clear a full environmental impact statement from the NRC with a recommendation that a construction permit be issued. For a technology class long trapped in pilot purgatory, breaking ground on a next-gen plant backed by Gates amounts to ringing the opening bell on an entirely new subsector of energy infrastructure.

Oklo: Microreactors for the AI Era

If TerraPower’s Natrium is the blue-chip utility play, Oklo (OKLO) is the growth stock pitching nuclear as a product for the AI age. Oklo is developing compact fast reactors—initially sub-100 megawatt units—that are designed to be factory-built, sited close to customers, and capable of running for years without refueling, eventually on recycled nuclear material. The goal is simple and audacious: turn nuclear power into something you buy in modular increments rather than as a once-in-a-generation mega-project.terrapower+1

That vision is already attracting data-center scale demand. Oklo has signed a framework agreement to deliver up to 12 gigawatts of nuclear capacity to Switch, a major data center operator whose client list includes the likes of Google and Nvidia, envisioning a fleet of microreactors rolled out through the 2040s. In parallel, Meta has lined up nuclear partnerships with Oklo, TerraPower, and others to secure roughly 6.6 gigawatts of power for its AI data centers by 2035—roughly the consumption of an entire small country. In effect, Oklo is sketching the blueprint for nuclear-powered digital campuses where the plant and the racks are designed as a single ecosystem, not separate line item.

Microsoft, Gates, and the AI Power Squeeze

All of this is unfolding against an uncomfortable arithmetic problem: AI is devouring electricity faster than grids can comfortably supply it. Forecasts suggest that data center demand could roughly double mid-decade, with AI-capable capacity growing north of 30% annually through 2030. Bill Gates has been blunt that nuclear energy is one of the few technologies capable of meeting that surge while keeping emissions in check, and TerraPower has already inked deals to serve next-generation data centers in regions where local power systems are stretched.

Microsoft, the company Gates co-founded and still influences as its most prominent alumnus, is increasingly vocal about needing new nuclear to power its cloud and AI ambitions, even going so far as to recruit small modular reactor expertise and explore nuclear-backed data center projects. That creates a neat symmetry: on one side, Gates’ TerraPower is building flexible, utility-scale reactors like Natrium; on the other, advanced players such as Oklo are designing microreactors and nuclear campuses that can plug almost directly into hyperscale facilities from Microsoft and its peers.

The result is a new strategic map where “compute” and “kilowatts” are no longer separate boardroom conversations. TerraPower’s Natrium plant in Wyoming shows that advanced reactors can clear regulatory hurdles and break ground; Oklo’s multi-gigawatt data center deals show that hyperscalers are ready to be anchor tenants; and the AI power squeeze ensures that Microsoft-level demand for firm, clean energy is not a passing fad but a structural feature of the next decade. For investors, the punchline is that nuclear is quietly reinventing itself as the backbone of the AI grid—with Bill Gates’ TerraPower providing the marquee project, Oklo supplying the modular edge, and Microsoft and its Big Tech cohort emerging as the sector’s most important new customers.

The Sources

  1. TerraPower – “NRC Approves the Natrium® Reactor Construction Permit”
    https://finance.yahoo.com/news/nrc-approves-natrium-reactor-construction-170100470.html[finance.yahoo]​
  2. Yahoo Finance – “Bill Gates-Backed TerraPower Wins Approval for 345-MW Natrium …”
    https://ca.finance.yahoo.com/news/bill-gates-backed-terrapower-wins-192554074.html[ca.finance.yahoo]​
  3. TerraPower – Natrium Advanced Reactor Overview
    https://www.terrapower.com/natrium/[terrapower]​
  4. TerraPower – “The Natrium® Project Receives First NRC-Issued Environmental Impact Statement for a Commercial Advanced Nuclear Reactor”
    https://www.terrapower.com/natrium-project-receives-first-nrc-issued-environmental-impact-statement-for-a-commercial-advanced-nuclear-reactor/[terrapower]​
  5. World Nuclear News – “US regulator accelerates review of Natrium permit”
    https://www.world-nuclear-news.org/articles/us-regulator-accelerates-review-of-natrium-permit[world-nuclear-news]​
  6. Axios – “Switch to buy 12 GW of nuclear from Oklo for data centers”
    https://www.axios.com/2024/12/18/switch-oklo-nuclear-data-centers[axios]​
  7. Utility Dive – “Oklo inks 12-GW advanced reactor supply agreement with data center developer Switch”
    https://www.utilitydive.com/news/oklo-aurora-smr-advanced-nuclear-reactor-supply-agreement-data-center-developer-switch/735933/[utilitydive]​
  8. NucNet – “Oklo Targets 12 GW Of New Nuclear Through Agreement With Data Centre Operator Switch”
    https://www.nucnet.org/news/oklo-targets-12-gw-of-new-nuclear-through-agreement-with-data-centre-operator-12-3-2024[nucnet]​
  9. Utility Dive – “Meta inks nuclear deals for up to 6.6 GW from Oklo, Vistra, TerraPower”
    https://www.utilitydive.com/news/meta-nuclear-deal-oklo-vistra-terrapower-ai-data-centers/809215/[utilitydive]​
  10. ESG News – “Meta Secures Up To 6.6 GW Nuclear Power To Fuel AI Data Center Growth”
    https://esgnews.com/meta-secures-up-to-6-6-gw-nuclear-power-to-fuel-ai-data-center-growth/[esgnews]​
  11. Power Magazine – “Meta Locks In Up to 6.6 GW of Nuclear Power Through Deals With Vistra, Oklo, and TerraPower”
    https://www.powermag.com/meta-locks-in-up-to-6-6-gw-of-nuclear-power-through-deals-with-vistra-oklo-and-terrapower/[powermag]​
  12. Yahoo Finance – “TerraPower and Meta Enter Agreement for 8 Natrium® Advanced Reactors …”
    https://finance.yahoo.com/news/terrapower-meta-enter-agreement-8-110100343.html[finance.yahoo]​
  13. Washington Is Pouring Billions Into Nuclear Energy. Does That … (Yahoo Finance)
    https://finance.yahoo.com/news/washington-pouring-billions-nuclear-energy-190200876.html[finance.yahoo]​

Intel’s Quiet Comeback: How a Boring Old Chip Giant Crashed the AI Party -( $INTC $MS $SPY )

Intel (INTC) is trying very hard to make “old-school silicon” sound like the hottest asset class in town—and, judging from its latest press run, the company may be getting somewhere.

A Boardroom Tune-Up for the AI PC Era

Intel’s most recent headline move isn’t a chip launch but a chair shuffle: longtime board chair Frank D. Yeary is stepping aside after the annual meeting, with Dr. Craig H. Barratt set to slide into the role. For a company in mid–turnaround, that’s less palace intrigue and more pit-stop engineering—refresh the driver while the car is finally picking up speed.

Barratt’s election signals a board leaning deeper into technology and execution, not just balance-sheet guardianship. Investors who have spent the last few years treating Intel like a “could-have-been” story will note that governance is now quietly catching up with the technology narrative—and in chip land, quiet changes on the board often precede louder ones in the income statement.newsroom.

Conferences, Firesides and the Art of Being Seen

The second and third items on Intel’s latest press slate are decidedly less glamorous but no less telling: a string of announcements that the company will participate in upcoming investor conferences, including a fireside chat featuring the CFO at a Morgan Stanley (MS) event. These aren’t just calendar fillers; they are how a legacy incumbent resets its relationship with Wall Street after several years of under-delivery and over-explaining.newsroom.

When a CFO volunteers for multiple fireside chats, it usually means two things: the numbers are becoming more predictable, and the company believes it finally has a story worth repeating. For portfolio managers juggling dozens of AI narratives, consistent visibility is the corporate equivalent of dollar-cost averaging—show up often enough, and eventually the story starts to stick.

From CES to 18A: The Technology Story Underneath

Though not one of the very latest filings, Intel’s January CES 2026 release keeps echoing through the more recent communications: the launch of Intel Core Ultra Series 3, the first PC platform built on the company’s 18A process. This is the technical backbone that gives all those conferences and governance tweaks something concrete to stand on.newsroom.

Intel is touting Series 3 as its most broadly adopted AI PC platform, with improvements in power efficiency, graphics and on-device AI compute that aim squarely at both consumer laptops and edge devices. That means the sleek ultrabook on your desk and the robot at the end of a factory line may soon share more DNA than some tech investors’ portfolios.

Why These Releases Matter for Investors

Taken together—the board succession, the investor-conference roadshow and the drumbeat around 18A-powered AI PCs—Intel is stitching a familiar but newly credible arc: tighten governance, sharpen the narrative, and point repeatedly to a flagship technology that could justify the capex hangover. None of these items is a blockbuster by itself, but in aggregate they suggest a company that finally realizes Wall Street doesn’t just want guidance; it wants a believable trajectory.

For investors, the question is no longer whether Intel wants to be central to the AI era—it clearly does—but whether this cadence of governance upgrades, public visibility and process-node execution can hold through the inevitable macro and competitive crosswinds. If it can, these press releases may read, in hindsight, less like routine corporate housekeeping and more like the first chapters of a very late but surprisingly lively comeback.newsroom.

The Sources

  1. Intel Board Chair Frank D. Yeary to Retire Following Annual Meeting; Dr. Craig H. Barratt Elected as Chair – Intel Investor Relations
    https://www.intc.com/news-events/press-releases/detail/1762/intel-board-chair-frank-d-yeary-to-retire-following-annual[intc]​
  2. Intel Board Chair Frank D. Yeary to Retire Following Annual Meeting; Dr. Craig H. Barratt Elected as Chair – Intel Newsroom
    https://newsroom.intel.com/corporate/intel-board-chair-frank-d-yeary-to-retire-following-annual-meeting-dr-craig-h-barratt-elect[newsroom.intel]​
  3. Intel Appoints Dr. Craig H. Barratt to Board of Directors – Intel Newsroom
    https://newsroom.intel.com/corporate/intel-appoints-dr-craig-h-barratt-to-board-of-directors[newsroom.intel]​
  4. CES 2026: Intel Core Ultra Series 3 Debut as First Built on Intel 18A – Intel Newsroom
    https://newsroom.intel.com/client-computing/ces-2026-intel-core-ultra-series-3-debut-first-built-on-intel-18a[newsroom.intel]​
  5. Intel Corporation to Participate in Upcoming Investor Conference (Morgan Stanley TMT fireside chat) – Intel Newsroom / Business Wire
    https://newsroom.intel.com/corporate/intel-to-participate-in-morgan-stanley-conference[newsroom.intel]​
  6. Intel Corporation to Participate in Upcoming Investor Conference – Business Wire / Nasdaq
    https://www.nasdaq.com/press-release/intel-corporation-participate-upcoming-investor-conference-2026-02-18[nasdaq]​
  7. Intel CFO David Zinsner Joins Morgan Stanley TMT Conference Fireside Chat at Revised Time – Sahm Capital
    https://www.sahmcapital.com/news/content/intel-cfo-david-zinsner-joins-morgan-stanley-tmt-conference-fireside-chat-at-revised-ti[sahmcapital]​
  8. Intel Debuts Core Ultra Series 3 on 18A at CES – TrendForce
    https://www.trendforce.com/news/2026/01/06/news-intel-debuts-core-ultra-series-3-on-18a-at-ces-highlights-igpu-gains-and-handhel[trendforce]​
  9. Intel Core Ultra Series 3 Debuts as First Built on Intel 18A – SemiWiki (syndicated press details)
    https://semiwiki.com/forum/threads/ces-2026-intel-core-ultra-series-3-debuts-as-first-built-on-intel-18a.24300/[semiwiki]​
  10. Intel Corporation to Participate in Upcoming Investor Conference – Investing News Network
    https://investingnews.com/intel-corporation-to-participate-in-upcoming-investor-conference/[investingnews]​

Actelis Catches the Green Light: Caltrans Deal Puts a Little Company in California’s Fast Lane -( $ASNS)

Actelis Networks (NASDAQ: ASNS) is hardly a household name, but in California’s latest highway overhaul, the quiet specialist in hybrid fiber-copper networking just got the green light in a big way. The company has landed an order from the California Department of Transportation (Caltrans) to provide networking gear for a roughly $120 million modernization project in San Mateo County, plugging its technology straight into the digital nervous system of a key Peninsula corridor.

A Small Cap in a Big-Cap World

In a market obsessed with trillion‑dollar tech giants, Actelis sits at the opposite end of the food chain, operating where the work boots, not the hoodies, tend to congregate. The company generated just $7.8 million in revenue in 2024, yet its technology already underpins air traffic control, telecom, energy infrastructure, and municipal systems—places where failure is frowned upon and pilot projects don’t graduate unless they pass the real‑world stress test.

Recent order activity hints that Actelis’ gear is doing more than passing; it is expanding. Within weeks of 2026’s opening bell, the company announced new and follow‑on orders from a major U.S. telecom carrier, a California municipality, and a European natural gas operator, signaling not one‑off wins but the early cadence of repeat business. For a company of this scale, a handful of multi‑site deployments can be the difference between “interesting niche vendor” and “quiet compounder.”

Why Caltrans Picked Copper’s Second Act

Caltrans’ San Mateo project is part of an approximately $120 million initiative to modernize a state route, with upgrades to traffic signals and monitoring systems across a heavily traveled stretch of the San Francisco Peninsula. Instead of ripping up miles of roadway for new fiber, the agency is leaning on Actelis’ MetaLight platform—a hybrid fiber-copper solution that delivers fiber‑grade connectivity over existing copper infrastructure.

The compact Ethernet access devices can be installed in minutes, support “drop‑and‑continue” topologies, and provide secure, high‑speed links between traffic management centers and a sprawl of roadside devices such as cameras, signal controllers, and monitoring stations. In plain English: Caltrans gets AI‑ready, cyber‑hardened networking for its signals and sensors without turning the Peninsula into a trenching exhibit—at a fraction of the cost and time of a pure‑fiber build. For taxpayers, that is the infrastructure equivalent of ordering the tasting menu and discovering it costs less than the appetizer.

Riding the Smart Transportation Wave

Actelis’ Caltrans deal slots neatly into a broader trend that is doing something rare in government spending: growing on purpose. North America’s smart transportation market is projected to approach $90 billion by 2026 as agencies digitize roads, deploy connected sensors, and push more intelligence to the edge of the network. Actelis pitches itself as a beneficiary of that shift, arguing that its technology provides rapid, cyber‑secure, and cost‑efficient networking exactly where transportation agencies are feeling pressure: at the roadside, where AI‑enabled cameras, cloud‑connected controllers, and security requirements all collide.

The Caltrans order adds to wins in Orange County and Ventura County in California, deployments in Washington, D.C., and projects across other municipalities and transportation agencies, creating a map of dots that is beginning to look less like isolated wins and more like a pattern. Transportation authorities, from the nation’s capital to the West Coast, are increasingly choosing the hybrid fiber-copper approach to upgrade legacy infrastructure quickly, then push more intelligence over the same network as needs evolve.

From Positioning to Execution

Inside the company, 2026 is being described as the year when Actelis shifts from lining up opportunities to executing on them. In a January 2026 letter, CEO Tuvia Barlev framed the year ahead as a transition from “positioning to execution,” citing accelerating modernization programs across federal, military, state, and transportation agencies and a rising need for secure edge connectivity to support AI and cloud workloads. Management’s stated playbook is simple enough: convert initial deployments into repeat orders, expand within approved customer footprints, increase software’s role to improve margins, and deliver steadier execution even as large infrastructure deals continue to follow their own calendar.

The Caltrans order offers a neat illustration of that strategy in motion. It is not a moon‑shot contract; it is a targeted deployment inside a much larger, roughly $120 million program, where performance can be measured, audited, and, if successful, scaled. For agencies, it limits risk. For Actelis, it opens doors for follow‑on orders as traffic networks grow denser, AI workloads move closer to the roadway, and cybersecurity expectations keep climbing. In that sense, the San Mateo corridor is more than a commute route; it is a live‑fire proving ground.

Investors Watch the On‑Ramp

The public markets have already signaled that they are paying attention, even if not yet fully convinced. Actelis trades on Nasdaq under the ticker ASNS, with investors weighing its growing list of infrastructure wins against questions about scale, capital needs, and execution in regulated markets where procurement cycles can stretch longer than a typical bull market. The company has faced its share of challenges, including a Nasdaq hearing request in early 2026 to address listing requirements, underscoring that small‑cap infrastructure plays rarely enjoy straight‑line progress.

Yet the gap between Actelis’ recent booking trends and its modest revenue base is precisely what some investors find intriguing. Customer bookings in late 2025 nearly doubled sequentially, and the company completed an approximately $500,000 order for the Federal Aviation Administration while lining up new follow‑on deployments into 2026. If execution tightens and contracts like Caltrans evolve from single orders into multi‑phase rollouts, Actelis’ annual revenue could plausibly move closer to, or even beyond, its recent market value—a reversal that tends to command more attention on Wall Street than any highway sign.

For now, the story is straightforward: a small networking company has become a quiet enabler of a high‑profile highway modernization, using old copper lines to deliver new digital capabilities. Caltrans gets faster, smarter, and more secure traffic infrastructure; drivers get a better‑managed commute; and Actelis gets something every small‑cap CEO likes to see in the rearview mirror—momentum.

The Sources

  1. StockTitan – “$120M California highway overhaul adds cyber-safe, AI-ready traffic control”
    https://www.stocktitan.net/news/ASNS/actelis-networks-wins-order-for-caltrans-california-department-of-0d77tzcbuhn2.html[stocktitan]​
  2. Yahoo Finance – “Actelis Networks Wins Order for Caltrans, California Department of Transportation”
    https://finance.yahoo.com/news/actelis-networks-wins-order-caltrans-140000933.html[finance.yahoo]​
  3. Actelis Networks (company site) – “Actelis Networks Wins Order for Caltrans, California Department of Transportation (Caltrans) Highway Modernization in San Mateo County”
    https://actelis.com/actelis-networks-wins-order-for-caltrans-highway-modernization-in-san-mateo-county/[actelis]​
  4. SwingTradeBot – “Actelis Networks Wins Order for Caltrans, California Department of Transportation”
    https://swingtradebot.com/news-articles/22518913-actelis-networks-wins-order-caltrans-california[swingtradebot]​
  5. Markets Insider – “Actelis Networks Wins Order for Caltrans, California Department of Transportation”
    https://markets.businessinsider.com/news/stocks/actelis-networks-wins-order-for-caltrans-california-department-of-transportation-[markets.businessinsider]​
  6. Reuters via TradingView – “Actelis Networks Wins Order For Caltrans, California Department Of Transportation”
    https://www.tradingview.com/news/reuters.com,2026:newsml_TUA615B5Y:0-actelis-networks-wins-order-for-caltrans-california-departm[tradingview]​
  7. StreetInsider – “Actelis Networks wins California highway modernization contract”
    https://www.streetinsider.com/Corporate+News/Actelis+Networks+wins+California+highway+modernization+contract/26088057.html[streetinsider]​
  8. Markets Insider – “Actelis Networks Appears to Be Gaining Momentum in 2026 as Infrastructure Orders Grow”
    https://markets.businessinsider.com/news/currencies/actelis-networks-appears-to-be-gaining-momentum-in-2026-as-infrastructure-or[markets.businessinsider]​
  9. Yahoo Finance – Actelis Networks, Inc. (ASNS) Quote Page
    https://finance.yahoo.com/quote/ASNS/[finance.yahoo]​
  10. CNBC – “ASNS: Actelis Networks Inc – Stock Price, Quote and News”
    https://www.cnbc.com/quotes/ASNS[cnbc]​
  11. Yahoo Finance – “Actelis Networks Receives Significant Expansion Order from Major …”
    https://finance.yahoo.com/news/actelis-networks-receives-significant-expansion-133000771.html[finance.yahoo]​

From Walled Gardens to Open Books: How DoubleVerify Makes Ad Tech Act Its Age-( $DV $SPY )

DoubleVerify (NYSE: DV) has spent the opening months of 2026 behaving less like an ad-tech vendor and more like a company intent on rewriting the operating manual for digital media trust.

Streaming TV Grows Up: DV’s CES Moment

At CES 2026, DoubleVerify rolled out DV Authentic Streaming TV, a new solution that wraps media quality, brand suitability and AI optimization into a single framework for connected TV and streaming inventory. The product taps program-level intelligence—think genre, maturity ratings, premiere dates, content trends and even viewer-approval scores—to help brands decide not just whether an ad ran, but whether it ran in the right context.

Under the hood, DV Authentic Streaming TV sits on the company’s Media AdVantage Platform, blending verification, AI-powered optimization and outcome measurement to turn what was once a black box of CTV impressions into a measurable performance channel. In an industry where nearly 70% of marketers say they can’t justify streaming investments without better transparency, DV is positioning its new tool as the answer to the CTV question that keeps CMOs up at night.

Earnings With an Algorithmic Tailwind

In its February 26 press release on fourth-quarter and full-year 2025 results, DoubleVerify reported continued growth in revenue and underscored the importance of AI-driven products across streaming, social and verification. Management paired that with a 2026 revenue growth target in the high single to low double digits, underlining confidence that the product roadmap—especially in CTV and social—is not just strategic window dressing but a core earnings driver.

Investors seemed to agree: following the results, DV shares moved sharply higher as the market digested the combination of solid execution, disciplined guidance and a pipeline of new AI-enhanced offerings. In a sector often punished for promising “AI” without a P&L to match, DoubleVerify is threading the needle by linking innovation explicitly to measurable campaign outcomes and revenue visibility.

Hitting the Investor Circuit

Barely a week after releasing earnings, DoubleVerify signaled it would keep the dialogue with Wall Street warm. On February 4, the company announced that CEO Mark Zagorski and CFO Nicola Allais will appear at the Citizens Technology Conference on March 3 and the Morgan Stanley Technology, Media & Telecom Conference on March 4. Both appearances will feature fireside chats, with live webcasts and archived replays available on the company’s investor relations site.e]​

Alongside those public sessions, DV plans one-on-one and small-group meetings with institutional investors, a clear cue that management is leaning into the role of “transparent counterparty” not only for buyers and sellers of ads, but for shareholders as well. For a company touting transparency as a product feature, an open Q&A on the tech-conference circuit is more than branding—it’s operational consistency.doubleverify+1

From Walled Gardens to Measured Gardens

DV’s recent releases build on a broader expansion across social and walled-garden platforms, where the company has layered its verification and measurement stack onto high-growth environments. In late 2025, DV extended its DV Authentic Attention product to TikTok as the first badged Marketing Partner for attention measurement using direct impression-level signals, giving advertisers metrics like Time In-View and engagement-based indices to fine-tune creative and spend. Around the same time, its 2025 Global Insights report on walled gardens highlighted how social platforms are reshaping advertising, commerce and news consumption, while brands push for transparency and addressability.

The common thread is a shift from simple viewability checks to a more nuanced model of media effectiveness—where attention, context and suitability work together to justify every dollar of digital spend. If advertising used to operate on the old “half my budget is wasted” joke, DV’s strategy suggests the new punchline is that the other half will be benchmarked, verified and optimized in real time.

An Ad-Tech Story With Adult Supervision

Taken together, the latest press releases paint a picture of a company trying to be the grown-up in a crowded, acronym-heavy corner of tech. Launching DV Authentic Streaming TV at CES addresses the most opaque corner of modern media, while the 2025 earnings print and 2026 growth target show there is real business behind the buzzwords. The upcoming investor conferences give management a prominent stage to reinforce that narrative and to translate AI, attention and verification into the traditional language of revenue, margin and returns on capital.

For search-savvy investors, marketers and analysts hunting for “DoubleVerify streaming TV,” “DV Authentic Attention,” “AI-powered ad verification” or “DoubleVerify 2025 earnings,” the story is increasingly consistent: this is a platform betting that transparency, measurement and media effectiveness can be both a competitive moat and a growth algorithm.

The Sources

  1. DoubleVerify Launches DV Authentic Streaming TV™ at CES 2026
    https://doubleverify.com/company/newsroom/doubleverify-launches-dv-authentic-streaming-tv-at-ces-2026[doubleverify]​
  2. DoubleVerify Launches DV Authentic Streaming TV™ at CES 2026 (Finance Yahoo syndication)
    https://finance.yahoo.com/news/doubleverify-launches-dv-authentic-streaming-140000745.html[finance.yahoo]​
  3. DoubleVerify to Participate in Upcoming Investor Conferences
    https://finance.yahoo.com/news/doubleverify-participate-upcoming-investor-conferences-210500833.html[finance.yahoo]​
  4. DoubleVerify to Participate in Upcoming Investor Conferences (alternate posting)
    https://longbridge.com/en/news/274867768[longbridge]​
  5. DoubleVerify Reports Fourth Quarter and Full Year 2025 Financial Results
    https://www.globenewswire.com/news-release/2026/02/26/3246093/0/en/DoubleVerify-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results.html[globenewswire]​
  6. DoubleVerify Reports Fourth Quarter and Full Year 2025 Financial Results (IR site entry)
    https://ir.doubleverify.com/news-events/press-releases/press-releases-details/2026/DoubleVerify-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results/default.aspx[ir.doubleverify]​

Genevant, Arbutus and Moderna: How a Once-in-a-Lifetime Pandemic Ended With a Once-in-a-Lifetime Check -( $MRNA $ABUS )

In the end, it was not a jury but a checkbook that settled one of biotech’s more closely watched intellectual-property dramas. Moderna will pay up to 2.25 billion dollars to Genevant Sciences and Arbutus Biopharma to resolve a global web of patent disputes over the lipid nanoparticle (LNP) delivery technology behind its COVID-19 vaccines, including Spikevax. For investors, the deal quietly rewrites the balance sheet of a small-cap hepatitis B specialist and its RNA-delivery affiliate—and offers a reminder that in biopharma, the most valuable molecules may be the ones you never see: the ones moving the cargo.

A Global Truce With a Global Price Tag

Under the settlement, Moderna agrees to a 2.25 billion dollar package that resolves all U.S. and international enforcement actions tied to its use of Genevant and Arbutus LNP patents in COVID-19 vaccines. Public disclosures indicate 950 million dollars will be paid upfront in July 2026, with an additional 1.3 billion dollars contingent on future events, placing the deal among the largest disclosed patent settlements in pharma history. In a sector where billion-dollar deals often buy pipelines or platforms, this one purchases peace—and a formal recognition that delivery technology was not just a footnote to the mRNA revolution.

From Courtroom Combat to Licensing Detente

The agreement does more than swap lawsuits for lump sums. Moderna receives a global non-exclusive license to use the LNP technology for infectious disease applications, along with a covenant not to sue covering specified Genevant/Arbutus patents and products. Moderna also acknowledges infringement and agrees not to challenge the validity of four key patents, a point the plaintiffs will likely frame as a legal—and reputational—win in a debate that has simmered since the height of the pandemic. The once-escalating enforcement campaign, which ranged from U.S. courts to international actions, is now replaced with something Wall Street tends to favor: predictable cash flows and fewer courtroom surprises.

The Quiet Power Behind mRNA’s Loud Success

For Genevant and Arbutus, the settlement is a validation campaign wrapped in legalese. Executives have long argued that Arbutus scientists “changed the drug development landscape” by inventing LNP delivery systems that enabled nucleic acids, including mRNA, to work as medicines rather than mere scientific curiosities. Genevant’s platform underpins the first and only approved systemic RNA-LNP product, patisiran, and has been studied across more than a dozen product candidates spanning vaccines, therapeutic protein production and gene editing. If mRNA was the headline act of the pandemic, LNP appears to be getting retroactive billing as the indispensable backstage crew—now with a substantial appearance fee.

Small-Cap, Big Check: What It Means for Arbutus and Roivant

The financial implications for Arbutus and its shareholder base are hard to ignore. Arbutus, a clinical-stage biotech focused on achieving a functional cure for chronic hepatitis B through assets like RNAi therapeutic imdusiran (AB-729) and oral PD-L1 inhibitor AB-101, now gains a sizeable external funding source just as its pipeline advances. Roivant, which co-founded Genevant and still highlights its LNP heritage alongside a portfolio that includes autoimmune and pulmonary programs, has already telegraphed plans to remain “capital efficient” with proceeds and has authorized an additional 500 million dollars in share repurchases. For investors used to thinking of LNP as enabling technology, the settlement reframes it as a free-standing asset class—one that can write its own dividend in the form of litigation-driven windfalls.

Beyond the Payout: IP, Incentives and the Next Wave of RNA

The Moderna deal also sends a message far beyond the parties involved. By affirming patent validity and converting contested IP into a licensed standard, the settlement may reduce uncertainty for future RNA and gene-editing developers who choose to build on established delivery platforms rather than reinvent them. It also reinforces a blunt incentive: in platform biotech, quietly curated IP estates can generate returns rivaling late-stage products, especially when global health emergencies move faster than licensing negotiations. For now, Genevant and Arbutus exit the courtroom with cash, credit and a newly clarified role in the RNA ecosystem—leaving investors to ponder an increasingly common biotech punchline: sometimes the real blockbuster is not the drug, but the envelope it came in.

The Sources


[1] Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion … https://sg.finance.yahoo.com/news/genevant-sciences-arbutus-biopharma-announce-211500258.html
[2] Arbutus Biopharma (ABUS) and Genevant Reach $2.25 Billion Settle https://www.gurufocus.com/news/8674939/arbutus-biopharma-abus-and-genevant-reach-225-billion-settlement-with-moderna
[3] Genevant Sciences and Arbutus Biopharma Announce $2.25 https://www.globenewswire.com/news-release/2026/03/03/3248939/14025/en/Genevant-Sciences-and-Arbutus-Biopharma-Announce-2-25-Billion-Global-Settlement-With-Moderna.html
[4] Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion … https://www.quiverquant.com/news/Genevant+Sciences+and+Arbutus+Biopharma+Announce+$2.25+Billion+Settlement+with+Moderna+Over+LNP+Technology+Patent+Infringement
[5] Genevant Sciences: Home https://www.genevant.com
[6] Roivant Announces Genevant Sciences’ and Arbutus https://www.globenewswire.com/news-release/2026/03/03/3248941/0/en/Roivant-Announces-Genevant-Sciences-and-Arbutus-Biopharma-s-2-25-Billion-Global-Settlement-With-Moderna.html
[7] Moderna to pay Genevant Sciences and Arbutus Biopharma up to … https://www.pharmalive.com/moderna-to-pay-genevant-sciences-and-arbutus-biopharma-up-to-2-25-billion-in-global-patent-settlement/
[8] Morrison Foerster Represented Arbutus in $2.25 Billion Global … https://www.mofo.com/resources/news/260303-arbutus-settlement-moderna
[9] Genevant Sciences and Arbutus Biopharma Initiate International … https://www.genevant.com/genevant-sciences-and-arbutus-biopharma-initiate-international-patent-infringement-enforcement-actions-against-moderna/
[10] Genevant inks development deal with BioNTech | BioPharma Dive https://www.biopharmadive.com/news/genevant-development-deal-biontech-roivant-rna-rare-disease/527444/
[11] [PDF] ARBUTUS BIOPHARMA CORP – OTC Markets https://www.otcmarkets.com/filing/conv_pdf?id=18917218&guid=n-3-ke0XjmwyvOh
[12] News – Genevant Sciences https://www.genevant.com/news/
[13] Arbutus and Roivant form Genevant Sciences – Lexpert https://www.lexpert.ca/big-deals/arbutus-and-roivant-form-genevant-sciences/351986
[14] Arbutus and Roivant Launch Genevant Sciences with … – SEC.gov https://www.sec.gov/Archives/edgar/data/1447028/000110465918023585/a18-9883_1ex7d05.htm
[15] Moderna Resolves Global Patent Litigation with Arbutus/Genevant https://www.palmbeachpost.com/press-release/story/154571/moderna-resolves-global-patent-litigation-with-arbutus-genevant/

From Wires to Wizards: How Nokia Is Teaching Networks to Code Themselves -( $GOOG $NOK $VOD )

Nokia’s (NOK) Network as Code platform is gaining global momentum, drawing major telecom giants into a collaborative ecosystem that promises to revolutionize programmable connectivity. With fresh partnerships and AI integrations, the Finnish telecom leader is scripting a narrative of innovation that’s as seamless as it is strategic.

Ecosystem Takes Flight

Nokia has welcomed heavyweights like Deutsche Telekom, Vodafone (VOD), Telefónica, Orange, Rakuten, Tata Communications, Globe, and TELUS into its Network as Code fold, pushing the partner tally beyond 75. This expansion, unveiled at MWC Barcelona, transforms labyrinthine telecom networks into developer-friendly APIs, much like turning a vintage telephone exchange into a sleek app store—efficient, accessible, and ripe for invention. Early adopters in banking, healthcare, and automotive are already crafting use cases that sidestep old-school hurdles like one-time passwords.

AI Agents Enter the Chat

Teaming with Google Cloud, Nokia is infusing agentic AI into the platform, enabling no-code workflows via Gemini models and protocols like Model Context Protocol. Imagine AI agents autonomously handling device management or fleet tracking, as if networks finally learned to read developers’ minds without needing a programmer’s séance. This fusion aligns with GSMA Open Gateway and CAMARA initiatives, accelerating secure, intent-based services for enterprises.

Real-World Wins Unfold

Deutsche Telekom powers Blocksport’s frictionless fan authentication, ditching OTPs for network-verified logins that keep sports enthusiasts in the game. Vodafone rolls out anti-fraud APIs across Europe for banking and e-commerce, while TELUS gears up for premium connectivity at major events like the World Cup. Tata Communications bolsters IoT in logistics with eSIM smarts, proving these APIs aren’t just talk—they’re delivering tangible traction.

Horizon of Programmable Promise

As Nokia’s platform matures since its 2023 launch, it’s unlocking monetization in antifraud, identity verification, and beyond, with demos lighting up MWC. Developers now enjoy standardized access across borders, fostering an era where networks don’t just connect—they anticipate and adapt with a wink of sophistication. This telecom renaissance positions Nokia at the vanguard of AI-driven connectivity.

The Sources

  1. Nokia expands Network as Code ecosystem, advances API-based agentic AI with Google Cloud (MWC26) – Nokia
    https://www.nokia.com/newsroom/nokia-expands-network-as-code-ecosystem-advances-api-based-agentic-ai-with-google-cloud-mwc26/
  2. Nokia Adds Vodafone, Telefonica, Other Telcos to Network-as-Code Platform – MarketScreener
    https://www.marketscreener.com/news/nokia-adds-vodafone-telefonica-other-telcos-to-network-as-code-platform-ce7e5cd2d98cff25
  3. Network as Code – Nokia
    https://www.nokia.com/programmable-networks/network-as-code/
  4. Network as Code for telecommunication providers – Nokia
    https://www.nokia.com/programmable-networks/network-as-code/telecommunication-providers/
  5. Network as Code: Home – Nokia
    https://networkascode.nokia.io
  6. From network APIs to network AI agents: Building the agentic future of connectivity with Google Cloud – Nokia
    https://www.nokia.com/blog/from-network-apis-to-network-ai-agents-building-the-agentic-future-of-connectivity-with-google-cloud/
  7. Nokia Expands Network as Code Ecosystem and Integrates Google Cloud Agentic AI – EuropaWire
    https://news.europawire.eu/nokia-expands-network-as-code-ecosystem-and-integrates-google-cloud-agentic-ai-to-transform-programmable-networks-into-intelligent-platforms-67890/eu-press-release/2026/03/02/
  8. Nokia Network as Code Google Cloud Integration – Intellectia
    https://intellectia.ai/news/stock/nokia-expands-network-as-code-initiative-with-google-cloud
  9. Google Cloud Announces Nokia Platform Integration at MWC – CX Today
    https://www.cxtoday.com/crm/nokia-network-as-code-google-cloud-integration/
  10. Telefónica and Nokia collaborate to accelerate network API adoption with agentic AI – TelecomTV
    https://www.telecomtv.com/content/apis/telef-nica-and-nokia-collaborate-to-accelerate-network-api-adoption-with-agentic-ai-54816/

Missiles and Microchips: Why Mobix Labs Just Became Wall Street’s New Crush -( $MOBX )

Mobix Labs (NASDAQ, MOBX) has quietly slipped a critical piece of technology into one of the U.S. Navy’s most visible weapons systems—and investors just noticed. A fresh production order tied to the Tomahawk cruise missile program has turned this fabless RF specialist into an unlikely protagonist in the defense-tech rally of early 2026.

A Small Filter in a Big Missile

At the heart of the news is a “high‑reliability filtering component” tucked inside the Tomahawk’s electronics, where it works as a sort of bouncer for stray signals. The part is engineered to mitigate electromagnetic interference, helping keep the missile’s sensitive onboard systems calm, coherent, and correctly pointed even in the kind of harsh conditions that make lesser circuits lose their composure.

The Navy’s latest production purchase order reflects increased procurement as Tomahawk manufacturing ramps, effectively scaling demand for the filter in lockstep with missile output. Because Mobix Labs is already fully qualified, integrated, and in the bill of materials, every incremental missile rolling off the line quietly pulls a Mobix component along for the ride.

From Niche RF Shop to Defense Platform Insider

Mobix Labs styles itself as a fabless semiconductor and connectivity company, focused on advanced wireless and wired connectivity, RF and millimeter‑wave solutions, and electromagnetic interference filtering. Historically, that has meant selling components and systems into a mix of defense, aerospace, industrial, medical, and 5G markets—a respectable but relatively low‑profile existence in the semiconductor ecosystem.

Defense, however, tends to reward persistence and qualification more than headline wattage, and Mobix has become an established supplier across several U.S. military platforms. The Tomahawk contract deepens that role by tying the company to an active U.S. strike system with meaningful production tempo, where component suppliers can see volumes rise not by marketing campaigns, but by procurement schedules.

The Market Reacts: A Missile‑Powered Melt‑Up

Wall Street, never one to ignore a good defense story in a jittery macro, responded with the subtlety of a launch sequence. Shares of Mobix Labs surged triple digits after the announcement, as traders repriced a business that had suddenly gone from “RF niche” to “embedded in a frontline missile program.” The stock, listed on the Nasdaq under the ticker MOBX, had previously traded with modest volume and mixed fundamentals, but the Navy order jolted both liquidity and attention.

The logic is straightforward: when production accelerates on an active defense platform and your part is already qualified, each new contract can scale like an annuity with boosters. In a market hungry for tangible growth narratives, a live missile line with rising procurement beats another hypothetical slide deck on “total addressable market” any day.

Beyond Tomahawk: Building a Broader Flight Path

The Tomahawk order is not a one‑off headline so much as a proof point in Mobix Labs’ broader push into defense, aerospace, and high‑reliability connectivity. Alongside missile components, the company’s portfolio spans mmWave 5G communications, RF integrated circuits, active optical cables, and EMI‑filtered interconnects aimed at customers who tend to care deeply about performance and not at all about buzzwords.

Recent FAA certification for the company’s drone‑based airborne sensing platform underscores that the same RF and interference‑management know‑how can travel from cruise missiles to critical‑infrastructure inspection at much lower altitudes—and friendlier use cases. For investors, the emerging thesis is that Mobix’s edge is less about any single product and more about a design‑in strategy across systems where failure is not an option, and where being quietly indispensable can be the loudest catalyst of all.

The Sources

  1. Yahoo Finance – Mobix Labs: U.S. Navy Tomahawk Missile Component Demand Rises
    https://finance.yahoo.com/news/mobix-labs-u-navy-tomahawk-144000119.html[finance.yahoo]​
  2. Business Wire – Mobix Labs: U.S. Navy Tomahawk Missile Component Demand Rises
    https://www.businesswire.com/news/home/20260303906147/en/Mobix-Labs-U.S.-Navy-Tomahawk-Missile-Component-Demand-Rises[businesswire]​
  3. Business Wire (via Yahoo Finance) – Mobix Labs Secures Significant U.S. Navy Tomahawk Missile Component Order as Production Accelerates
    https://finance.yahoo.com/news/mobix-labs-secures-significant-u-123000531.html[finance.yahoo]​
  4. Nasdaq – Mobix Labs Secures U.S. Navy Tomahawk Missile Component Order, Stock Soars
    https://www.nasdaq.com/articles/mobix-labs-secures-us-navy-tomahawk-missile-component-order-stock-soars[nasdaq]​
  5. Investing.com – Mobix Labs Stock Soars 250% on Navy Missile Order
    https://www.investing.com/news/stock-market-news/mobix-labs-stock-soars-250-on-navy-missile-order-93CH-4538578[investing]​
  6. Investing.com – Mobix Labs Receives Production Order for Tomahawk Missile Parts
    https://uk.investing.com/news/company-news/mobix-labs-receives-production-order-for-tomahawk-missile-parts-93CH-4537106[uk.investing]​
  7. StockTitan – Mobix Labs: The Tiny Part Shielding Electronics in U.S. Navy Tomahawk Missiles
    https://www.stocktitan.net/news/MOBX/mobix-labs-secures-significant-u-s-navy-tomahawk-missile-component-3qw8pmt3qky7.html[stocktitan]​
  8. Business Wire (syndicated) – Mobix Labs Secures Significant U.S. Navy Tomahawk Missile Component Order
    https://www.businesswire.com/news/home/20260303370631/en/Mobix-Labs-Secures-Significant-U.S.-Navy-Tomahawk-Missile-Component-Order[businesswire]​
  9. Morningstar (syndicated Business Wire release) – Mobix Labs Secures Significant U.S. Navy Tomahawk Missile Component Order
    https://www.morningstar.com/news/business-wire/20260303370631/mobix-labs-secures-significant-us-navy-tomahawk-missile-component-order[morningstar]​
  10. TipRanks / The Fly – Mobix Labs Gets Production Purchase Order for Tomahawk Cruise Missile Components
    https://www.tipranks.com/news/the-fly/mobix-labs-gets-production-purchase-order-for-tomahawk-cruise-missile-components-thefly-ne[tipranks]​

March 3, 2026 – Oil Shock and War Fears Rattle Wall Street: Major Indexes Slide Despite Late Comeback -( $ASTS $GOVX $KTB $INTA $INTM $MOBX $MODD $SOAR Rise!)

US stocks fell sharply Tuesday but closed well off their intraday lows as investors weighed an escalating war in Iran, a spike in oil, and the risk of stickier inflation. The Dow, S&P 500, and Nasdaq all finished lower for a second straight session after recovering from losses that at one point exceeded 1,000 points on the blue-chip index.

Index performance

Major averages staged a notable intraday comeback but still ended solidly in the red.

  • Dow Jones Industrial Average: closed down roughly 0.83%, or about 400 points, after earlier tumbling more than 1,200 points.
  • S&P 500: finished lower by about 0.94%, after being down more than 2% at the lows.
  • Nasdaq Composite: declined around 1.02%, leading the downside as growth and tech names remained under pressure.

Breadth was weak, with decliners far outpacing gainers, and risk appetite stayed subdued despite the late-session stabilization.

Geopolitics, oil, and inflation

The session was dominated by headlines out of the Middle East as U.S. and Israeli strikes on Iranian targets continued and Tehran expanded attacks on energy infrastructure and shipping in the region. Nearly halted tanker traffic through the Strait of Hormuz and strikes on facilities across multiple countries fueled a sharp move higher in crude and refined products.

Brent crude briefly traded above the mid‑80s before settling around the low‑80s, up roughly 5% on the day, while U.S. benchmarks gained in the high‑single‑digit percentage range. Heating oil, gasoline, and natural gas futures also jumped, reinforcing worries that higher energy costs could re‑ignite inflation just as the Federal Reserve was expected to move toward rate cuts.

Rates, safe havens, and sentiment

Rising oil and war uncertainty pushed investors into classic safe havens, lifting the dollar while pressuring risk assets. Gold futures 3.70% as the dollar index advanced..

U.S. Treasury yields rose earlier as traders priced in the inflationary impact of oil, with the 10‑year note yield moving above 4% before easing back to just over 4.05% into the close. This back‑and‑forth in yields mirrored shifting expectations around how much the conflict could complicate the Fed’s path and delay any pivot to easier policy.

Sector and stock movers

Energy shares outperformed as investors rotated toward perceived winners from higher crude prices, while economically sensitive and rate‑sensitive pockets lagged.

  • Energy: Oil and gas producers, refiners, and services names benefited from the spike in crude and product prices
  • Cyclicals and small caps: Industrials, materials, and smaller domestically focused companies underperformed amid fears of slower growth and higher input costs
  • Tech and growth: High‑multiple tech and communication stocks saw outsized selling as investors de‑risked and reassessed valuations in a higher‑for‑longer inflation scenario
  • Kontoor Brands (KTB), Ingram Micro (INGM), Intapp (INTA), and several growth and cyclicals posted outsized gains on Tuesday, standing out against a risk‑off tape driven by Iran war concerns. The common thread across most of these movers was either fresh guidance, earnings momentum, or direct leverage to themes like defense, energy, and productivity software.
  • AST SpaceMobile (ASTS, $92.68, +6.63%) reported its first full year of meaningful revenue in 2025, delivering approximately 70.9 million dollars, at the high end of its guidance range. That top line is driven largely by two engines: mobile network operator (MNO) partners and the U.S. Government, a pairing that would make most telecom CFOs nod approvingly.Product revenue has begun to scale as AST SpaceMobile shipped 15 gateway sites across five continents, effectively seeding the ground segment for its space‑based cellular network. On the services side, multiple U.S. Government contracts are already producing revenue as agencies test specialized use cases for the company’s direct‑to‑device architecture.

Even with some late‑day bargain hunting, the tone across sectors reflected a classic risk‑off posture centered on war, oil, and inflation rather than company‑specific news.

Big picture

The market’s ability to retrace a large portion of its early plunge suggests investors are not yet pricing in a worst‑case scenario, but volatility around geopolitical headlines remains elevated. With the Iran conflict threatening key energy infrastructure and shipping lanes, traders are increasingly focused on whether a sustained oil shock could derail disinflation progress and force the Fed to stay restrictive longer than anticipated.finance.

VP Watchlist Updates

Below is an update‑style snapshot on the VP Watchlist names for the week, focused on recent catalysts, positioning, and narrative rather than precise price moves.

Eupraxia Pharmaceuticals (EPRX, $8.02)

Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, recently announced the successful closing of its previously announced public offering (the “Offering”) of 7,607,145 common shares of the Company (the “Common Shares”), which includes the full exercise of the option to purchase additional shares granted to the underwriters, at a price to the public of US$7.00 per Common Share, and pre-funded warrants to purchase up to 1,428,571 Common Shares in lieu thereof (the “Pre-Funded Warrants”) at a price of US$6.99999 per Pre-Funded Warrant, which equals the public offering price per Common Share less the C$0.000001 per share exercise price of each Pre-Funded Warrant, for gross proceeds of approximately US$63.2 million, before deducting the underwriting commissions and estimated expenses incurred in connection with the Offering.“We are pleased to complete this financing, allowing us to significantly expand our pipeline, reach several additional development milestones with EP-104GI for eosinophilic esophagitis, and make meaningful progress towards commercial readiness,” said James Helliwell, CEO of Eupraxia. “We appreciate the support from both existing and new investors as we execute our mission and pursue the next phase of growth for Eupraxia.” Cantor and LifeSci Capital acted as joint book-running managers for the Offering. Bloom Burton and Craig-Hallum also acted as co-managers for the Offering. As previously stated, the Company intends to use the net proceeds from the Offering primarily for the continued advancement of EP-104GI for Eosinophilic Esophagitis, including the completion of ongoing preclinical studies, and Phase 2 clinical trials, preparations for a Phase 3 clinical trial including the related regulatory submissions, and manufacturing activities, and to undertake the necessary commercial/market development activities to prepare for the eventual product launch. The Company also intends to use a portion of the proceeds to accelerate and expand its plans to pursue clinical studies with EP-104GI in multiple additional gastrointestinal indications, including in esophageal strictures and fibrostenotic Crohn’s disease. A portion of the proceeds will be allocated to research and development of additional pipeline candidates, business development initiatives, and general corporate purposes, which may include but are not limited to employee salaries, working capital, leases for facilities, administrative expenses, and capital expenditures. The Company may also use a portion of the proceeds to expand its intellectual property portfolio and strengthen its corporate infrastructure to support future growth.

Modular Medical (MODD $.168, +7.01%)

FIGS, Inc. (FIGS, $16.96)

  • FIGS, the direct‑to‑consumer healthcare apparel brand, operates at the intersection of e‑commerce and specialty retail, with a loyal professional customer base and a growing product portfolio. While macro headwinds and digital‑ad volatility have pressured some consumer names, FIGS’ brand equity in the medical community and ongoing product innovation offer levers for renewed growth as conditions normalize.
  • After the close (Feb. 26), FIGS released its fourth quarter and full year 2025 financial results and published a financial highlights presentation on its investor relations highlighting the following: Exceeded Top and Bottom Line Expectations, Grew Q4 2025 Net Revenues 33.0% to a Record $201.9 Million, Achieved Q4 2025 Net Income Margin of 9.2% and Adjusted EBITDA Margin of 13.2% & Plans Low Double-Digit Net Revenues Growth and Margin Expansion in FY 2026. FIGS shares have traded up to $13.74 in the aftermarket today.

GeoVax Labs (GOVX, $1.57, +.64%)

DoubleVerify (DV, $10.16)

  • DoubleVerify, the leading software platform for digital media measurement, data and analytics, today announced financial results for the fourth quarter and full year ended December 31, 2025 and highlighted the following: Increased 2025 Revenue by 14% Year-over-Year to $748.3 Million, Driven by Global Growth in Social, CTV Measurement, and Programmatic Activation, Achieved 2025 Net Income of $50.7 Million and Adjusted EBITDA of $245.6 Million, representing a 33% Adjusted EBITDA margin, & $300 Million Authorized for Share Repurchases, the Largest Amount in DoubleVerify’s History.

The InterGroup Corporation (INTG, $31.32)

  • InterGroup Corporation delivered (Feb. 17) a notably stronger quarter, highlighted by a 20% jump in total revenue to $17.3 million and a 27% surge in hotel revenue as renovated rooms returned to service and travel demand improved. The company swung from a prior-year net loss to $1.0 million in net income, with operating income more than doubling to $2.0 million, underscoring better cost control and improved operating efficiency. Management further enhanced liquidity and sharpened strategic focus by selling a non-core 12‑unit Los Angeles multifamily property, generating a meaningful gain and additional working capital while maintaining stable performance across its real estate portfolio.

Serina Therapeutics (SER, $1.77)

  • Serina Therapeutics, a clinical-stage biotechnology company advancing drug candidates enabled by its proprietary POZ Platform™ drug optimization technology, announced (Feb. 19) that the first patient has been enrolled in the Company’s Phase 1b registrational trial evaluating. The Phase 1b registrational study is designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of SER-252 in patients with advanced Parkinson’s disease whose symptoms are inadequately controlled by current standard-of-care therapies. Serina remains on track to initiate dosing during the current quarter, consistent with previously disclosed guidance.

Volato Group, Inc. (SOAR, $3386, +7.12%) & M2i Global, Inc. (MTWO)

  • Volato and M2i Global reaffirmed their goal of closing their business combination in the first quarter of 2026, citing steady advancement through SEC review and integration planning as they move toward a combined listing. The deal, originally announced in 2025, will effectively transition Volato from a pure‑play private aviation operator into a diversified platform spanning aviation technology and critical minerals, with M2i shareholders expected to own the majority of the combined entity. Operationally, the partnership is already visible: the two companies recently initiated their first shipment of titanium ore from Western Australia to the United States from Titanium X, underscoring how the critical‑minerals vertical could become a meaningful growth engine as domestic supply‑chain security rises in strategic importance.
  • On Feb. 4, M2i Global,Inc.along with Volato Group, Inc. announced that Titanium X has initiated its first shipment of titanium ore from Western Australia to the U.S. under its collaboration agreement.

NVIDIA (NVDA, $180.05)

  • Nvidia delivered strong fourth-quarter results recently, posting revenue of $68.1 billion, well above analyst expectations. Looking ahead, the company projects $7.8 billion in revenue for the first quarter of 2026, reflecting continued robust demand for its AI chips even amid broader market headwinds.

McDonald’s (MCD, $332.17)

  • Options data around the February 2026 expiries highlight active positioning near the 300–305 strike range, consistent with expectations for steady but not explosive upside from here.
  • In the run-up to World Protein Day on 27th February, McDonald’s India (West & South), owned and operated by Westlife Foodworld, is celebrating Protein Week, reinforcing its leadership in nutrition-led innovation. Making protein more accessible, affordable and customizable, Indian consumers can use the McDonald’s app to explore these nutritious offerings and avail of protein burgers starting at just INR 69. Enhancing this convenience, consumers ordering via McDelivery can also enjoy free delivery on the Protein Plus meal range.

Nokia (NOK, $8.07)

Opendoor (OPEN, $4.97)

Mobix Labs (MOBX, $1.12, +532.77%)

Mobix Labs, Inc. (Nasdaq: MOBX) today issued a brief update following its earlier announcement of a production purchase order supporting the U.S. Navy’s Tomahawk cruise missile program, emphasizing that the order reflects increased procurement associated with ongoing missile production. The order supports near-term manufacturing schedules and increased volumes of Mobix Labs’ high-reliability filtering component—an already-qualified, mission-essential part integrated into the established defense production supply chain. Mobix Labs continues to support multiple active U.S. military platforms and remains focused on disciplined execution across defense and aerospace programs requiring production-ready, high-reliability components.

The Sources

  1. Yahoo Finance – “Dow, S&P 500, and Nasdaq slide as oil rises amid war worries”
    https://finance.yahoo.com/news/live/stock-market-today-dow-sp-500-and-nasdaq-slide-as-oil-rises-amid-war-worries-193537739.html[finance.yahoo]​
  2. Yahoo Finance – “Stocks set to slide as investors focus on the Iran war’s impact on oil”
    https://finance.yahoo.com/news/stocks-set-slide-investors-focus-133245686.html[finance.yahoo]​
  3. Yahoo Finance – “Stock market today: Dow, S&P 500, Nasdaq trim losses but end sharply lower as Wall Street assesses Iran war worries”
    https://nz.finance.yahoo.com/news/stock-market-today-dow-sp-500-nasdaq-futures-sink-as-iran-conflict-escalates-235309346.html[nz.finance.yahoo]​
  4. CNBC – “Stock market news for March 3, 2026”
    https://www.cnbc.com/2026/03/02/stock-market-today-live-updates.html[perplexity]​
  5. Wall Street Journal – “Stock Market Today: Dow Pares Early Decline, Oil Climb Moderates”
    https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-03-03-2026[wsj]​
  6. Barron’s – “Dow Dives as Iran Attacks Spread”
    https://www.barrons.com/livecoverage/stock-market-news-today-030326[barrons]​
  7. Reuters – “US stocks pull back as Iran war concerns deepen”
    https://www.reuters.com/business/us-stocks-sell-off-iran-war-concerns-deepen-2026-03-03/[reuters]​
  8. CNN Business – “Stocks sink as Wall Street fears a prolonged war with Iran”
    https://www.cnn.com/2026/03/03/investing/us-stocks-iran[cnn]​
  9. MarketWatch – “Stock Market Today: Dow down 250 points, S&P 500 and Nasdaq …”
    https://www.marketwatch.com/livecoverage/stock-market-today-dow-sp500-nasadq-lower-oil-up-iran-war-korea-dives[marketwatch]​
  10. TradingView – “Why Kontoor Brands (KTB) Stock Is Up Today”
    https://www.tradingview.com/news/stockstory:713d34832094b:0-why-kontoor-brands-ktb-stock-is-up-today/[tradingview]​
  11. Yahoo Finance – “Why Kontoor Brands (KTB) Stock Is Up Today”
    https://finance.yahoo.com/news/why-kontoor-brands-ktb-stock-190742683.html[finance.yahoo]​
  12. Yahoo Finance – “Why Kontoor Brands Stock Popped Today”
    https://finance.yahoo.com/news/why-kontoor-brands-stock-popped-183331690.html[finance.yahoo]​
  13. MarketBeat – “Kontoor Brands (NYSE:KTB) Shares Gap Up on Better-Than-Expected Earnings”
    https://www.marketbeat.com/instant-alerts/kontoor-brands-nysektb-shares-gap-up-on-better-than-expected-earnings-2026-03-03/[marketbeat]​
  14. StockTitan – “Kontoor Brands (NYSE: KTB) boosts 2026 outlook after Helly …”
    https://www.stocktitan.net/sec-filings/KTB/8-k-kontoor-brands-inc-reports-material-event-53767053bfbb.html[stocktitan]​
  15. MarketBeat – “Ingram Micro (NYSE:INGM) Issues Q1 2026 Earnings Guidance”
    https://www.marketbeat.com/instant-alerts/ingram-micro-nyseingm-issues-q1-2026-earnings-guidance-2026-03-03/[marketbeat]​
  16. GuruFocus – “Ingram Micro (INGM) Sees Significant 17.1% Share Price Increase”
    https://www.gurufocus.com/news/8674227/ingram-micro-ingm-sees-significant-171-share-price-increase[gurufocus]​
  17. MarketBeat – “Intapp (NASDAQ:INTA) Trading 5% Higher – Still a Buy?”
    https://www.marketbeat.com/instant-alerts/intapp-nasdaqinta-trading-5-higher-still-a-buy-2026-03-03/[marketbeat]​
  18. MarketBeat – “Intapp (NASDAQ:INTA) Cut to ‘Buy’ at Wall Street Zen”
    https://www.marketbeat.com/instant-alerts/intapp-nasdaqinta-cut-to-buy-at-wall-street-zen-2026-03-02/[marketbeat]​
  19. Tickeron – “Why Did AeroVironment, Inc. (AVAV) Stock Move Up +16.83% Today?”
    https://tickeron.com/blogs/why-did-aerovironment-inc-avav-stock-move-up-16-83-today-11802/[tickeron]​
  20. Investing.com – “Tidewater March 2026 slides: dominant OSV position after Q4 beat”
    https://ng.investing.com/news/company-news/tidewater-march-2026-slides-dominant-osv-position-after-q4-beat-93CH-2371807[ng.investing]​
Your Guide To Staying Informed In The Markets

Subscribe For Free Email Updates Access To Exclusive Research

Vista Partners — © 2026 — Vista Partners LLC (“Vista”) is a Registered Investment Advisor in the State of California. Vista is not licensed as a broker, broker-dealer, market maker, investment banker, or underwriter in any jurisdiction. By viewing this website and all of its pages, you agree to our terms. Read the full disclaimer here